Optimizing Anemia Management and Addressing Unmet Needs in LR MDS
- Please share your key takeaways for optimizing anemia management in lower-risk MDS, and where do you see the most significant unmet needs?
- What remain the key unmet needs in treating anemia and improving outcomes for lower-risk MDS patients despite the availability of therapies like imetelstat, luspatercept, and ESAs?
- Are there any emerging agents, combination regimens, or ongoing trials in the pipeline?
Recent Videos
Related Content
